Kolexia
Banos Anne Oncologie hémato.
Banos Anne
Oncologie hémato.
Centre Hospitalier de la Côte Basque
Bayonne, France
172 Activités
7 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Myélome multiple Leucémie aigüe myéloïde Lymphomes Leucémie myéloïde Syndromes myélodysplasiques Tumeurs à plasmocytes Récidive tumorale locale Leucémie lymphoïde

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Tournilhac Olivier
Tournilhac Olivier
Hôpital Estaing, Clermont-Ferrand, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France
Cartron Guillaume
Cartron Guillaume
Hôpital Saint-Éloi, Montpellier, France

Industries

Voir plus
Abbvie
9 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2021
Novartis
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Essai Clinique (Syros Pharmaceuticals)   17 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023
Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Blood advances   23 octobre 2023
DEXAML-03: Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study
Essai Clinique (CHU Toulouse)   20 septembre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Genetic alterations and MRD refine risk assessment within KMT2A-rearranged B-cell precursor ALL in adult: a GRAALL study.
Blood   18 août 2023